Time to refocus on HSV interventions for HIV prevention?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. HIV and herpes simplex virus type 2 epidemiological synergy: misguided observational evidence? A modelling study.Sexually transmitted infections · 2018
   Pooled it
2. Global population-level association between herpes simplex virus 2 prevalence and HIV prevalence.AIDS (London, England) · 2018
   Pooled it
3. Sexual network drivers of HIV and herpes simplex virus type 2 transmission.AIDS (London, England) · 2017
   Article
4. Comparative performance of the Uni-Gold™ HSV-2 Rapid: a point-of-care HSV-2 diagnostic test in unselected sera from a reference laboratory.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2014
   Article
5. Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?AIDS (London, England) · 2013
   Article
6. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.Current HIV research · 2012
   Review

Corrections and comments

• Comment on
  Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.2008
• Comment on
  Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.2010
• Comment on
  High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.2011

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as